1\. Introduction Scheduled surgery requires patients to undergo a preoperative fasting period of at least 6 hours to ensure an empty stomach, significantly reducing the risk of perioperative aspiration pneumonia. However, certain medications and/or conditions have been described that can cause delayed gastric emptying, potentially placing patients at risk for aspiration; among these entities are diabetic gastroparesis and the use of GLP-1 analogs as a treatment for diabetes. Glucagon-like peptide-1 (GLP-1) is an intestinal hormone with beneficial effects on blood glucose control. It stimulates insulin release, reduces glucagon production, and decreases appetite, making it a therapeutic tool for the treatment of type 2 diabetes and obesity. GLP-1 receptor agonists have been approved by the FDA for these indications, and their use is continuously increasing. One of the primary side effects of GLP-1 agonists is delayed gastric emptying, which can lead to nausea, vomiting, and abdominal distension. Recent scientific literature has presented multiple reports demonstrating delayed gastric emptying associated with the use of GLP-1 agonists, including cases of pulmonary aspiration during anesthesia (despite adequate fasting periods). These findings underscore the necessity for anesthesiologists and perioperative physicians to be aware of the potential risks associated with these medications. It is suggested that these drugs be discontinued days prior to elective surgical procedures, depending on dosing frequency. It is essential to assess the presence of gastrointestinal symptoms, as they may indicate an increase in residual gastric content and heighten the risk of complications. As the use of GLP-1 agonists continues to expand, it is crucial to recognize and manage the risks associated with delayed gastric emptying in patients utilizing these agents. Further research is needed to establish more precise guidelines and mitigate the perioperative risks associated with these drugs.